NasdaqCM - Delayed Quote USD

Curis, Inc. (CRIS)

14.52

-0.25

(-1.69%)

At close: April 25 at 4:00 PM EDT

Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?

Curis (CRIS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks 20 days ago

CRIS
-1.69%
MRSN
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April 1, 2024, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 8,550 shares of Curis common stock to a new employee, with a grant date of April 1, 2024 (the "Q2 2024 Inducement Grant").

PR Newswire 20 days ago

CRIS
-1.69%
Curis to Present at Upcoming Healthcare Conferences in April

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the 23rd Annual Needham Virtual Healthcare Conference being held on April 8 - 11, 2024. Presentation details are as follows:

PR Newswire 21 days ago

CRIS
-1.69%
Curis, Inc. (NASDAQ:CRIS) Q4 2023 Earnings Call Transcript

Curis, Inc. (NASDAQ:CRIS) Q4 2023 Earnings Call Transcript February 8, 2024 Curis, Inc. misses on earnings expectations. Reported EPS is $-2.03 EPS, expectations were $-1.91. Curis, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to […]

Insider Monkey 2 months ago

CRIS
-1.69%
Curis Provides Fourth Quarter 2023 Business Update

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the quarter ended December 31, 2023.

PR Newswire 2 months ago

CRIS
-1.69%
Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will release its fourth quarter 2023 financial results on Thursday, February 8, 2024, at 8:00 a.m. ET. Management will host a conference call at 8:30 a.m. ET.

PR Newswire 2 months ago

CRIS
-1.69%
Curis, Inc. (NASDAQ:CRIS) Surges 54% Yet Its Low P/S Is No Reason For Excitement

Curis, Inc. ( NASDAQ:CRIS ) shareholders would be excited to see that the share price has had a great month, posting a...

Simply Wall St. 4 months ago

CRIS
-1.69%
Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced initial combination study data from its TakeAim Lymphoma trial including 5 primary CNS lymphoma (PCNSL) patients.

PR Newswire 4 months ago

CRIS
-1.69%
Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, last night presented clinical data from its TakeAim Leukemia Study at the 2023 ASH Conference.

PR Newswire 4 months ago

CRIS
-1.69%
Curis Announces Three Presentations at ASH

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company along with its collaborative partners will be presenting three posters at the upcoming 65th ASH Annual Meeting and Exposition (ASH 2025) being held in San Diego, California and online from December 9th to December 12th.

PR Newswire 4 months ago

CRIS
-1.69%
Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that it has entered into an investigator-initiated clinical trial agreement with the University of Florida to study the combination of emavusertib and pembrolizumab in patients with metastatic melanoma.

PR Newswire 4 months ago

CRIS
-1.69%
Curis, Inc. (NASDAQ:CRIS) Q3 2023 Earnings Call Transcript

Curis, Inc. (NASDAQ:CRIS) Q3 2023 Earnings Call Transcript November 2, 2023 Curis, Inc. beats earnings expectations. Reported EPS is $-2.13, expectations were $-2.32. Operator: Good morning, and welcome to Curis’ Third Quarter 2023 Business Update Call. All participants will be in a listen-only mode. [Operator Instructions] After the company’s prepared remarks, all participants will have […]

Insider Monkey 5 months ago

CRIS
-1.69%
Curis Inc (CRIS) Reports Q3 2023 Financial Results: Net Loss Decreases Year-Over-Year

Company Continues Progress on Emavusertib Development, Maintains Strong Balance Sheet

GuruFocus.com 5 months ago

CRIS
-1.69%
Curis Provides Third Quarter 2023 Business Update

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies, today reported its business update and financial results for the quarter ended September 30, 2023.

PR Newswire 5 months ago

CRIS
-1.69%
2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Should You Buy?

2seventy bio, Inc. (TSVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 5 months ago

CRIS
-1.69%
Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies, today announced that the Company will release its third quarter 2023 financial results on Thursday, November 2, 2023, at 8:00 a.m. ET. Management will host a conference call on the same day at 8:30 a.m. ET.

PR Newswire 5 months ago

CRIS
-1.69%
We're Hopeful That Curis (NASDAQ:CRIS) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Simply Wall St. 5 months ago

CRIS
-1.69%
Pharming Group N.V. Sponsored ADR (PHAR) Soars 14.7%: Is Further Upside Left in the Stock?

Pharming Group N.V. Sponsored ADR (PHAR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks 6 months ago

PHARM.AS

CRIS
-1.69%
Curis Announces Date for the 2nd Symposium on IRAK4 in Cancer

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies, today announced the 2nd Symposium on IRAK4 in Cancer taking place virtually on September 22, 9:00am-1:00pm ET.

PR Newswire 7 months ago

CRIS
-1.69%
Curis to Present at Upcoming Healthcare Conferences in September

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule IRAK4 inhibitor for the treatment of hematologic malignancies, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences:

PR Newswire 7 months ago

CRIS
-1.69%

Performance Overview

Return	CRIS	S&P 500
YTD	+13.88%	+5.84%
1-Year	+1,715.00%	+22.03%
3-Year	+36.98%	+20.77%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Curis, Inc. (CRIS)

Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis to Present at Upcoming Healthcare Conferences in April

Curis, Inc. (NASDAQ:CRIS) Q4 2023 Earnings Call Transcript

Curis Provides Fourth Quarter 2023 Business Update

Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024

Curis, Inc. (NASDAQ:CRIS) Surges 54% Yet Its Low P/S Is No Reason For Excitement

Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study

Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference

Curis Announces Three Presentations at ASH

Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma

Curis, Inc. (NASDAQ:CRIS) Q3 2023 Earnings Call Transcript

Curis Inc (CRIS) Reports Q3 2023 Financial Results: Net Loss Decreases Year-Over-Year

Curis Provides Third Quarter 2023 Business Update

2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Should You Buy?

Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023

We're Hopeful That Curis (NASDAQ:CRIS) Will Use Its Cash Wisely

Pharming Group N.V. Sponsored ADR (PHAR) Soars 14.7%: Is Further Upside Left in the Stock?

Curis Announces Date for the 2nd Symposium on IRAK4 in Cancer

Curis to Present at Upcoming Healthcare Conferences in September

Performance Overview